Effect of serum lipoproteins and cholesterol on an exogenous pulmonary surfactant. ESR analysis of structural changes and their relation with surfactant activity

Respiratory Physiology and Neurobiology

Volumn 189, Issue 3, 2013, Pages 581-587

  Martínez Sarrasague, María ^a   Cimato, Alejandra ^a   Piehl, Lidia ^a   Brites, Fernando ^a   Facorro, Graciela ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cholesterol; ESR; Exogenous pulmonary surfactant; Serum lipoproteins; Structural changes

Indexed keywords

ALBUMIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LUNG SURFACTANT; PROSURF; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BIOLOGICAL ACTIVITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; MEMBRANE FLUIDITY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; SURFACE TENSION;

CHOLESTEROL; ESR; EXOGENOUS PULMONARY SURFACTANT; SERUM LIPOPROTEINS; STRUCTURAL CHANGES;

CHOLESTEROL; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; LIPOPROTEINS; PULMONARY SURFACTANTS; SURFACE TENSION;

EID: 84888011634     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2013.08.004     Document Type: Article

References (55)

1. Allain C.C., Poon L.S., Chan C.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin. Chem. 1974, 20(April (4)):470-475.
2. Alonso C., Alig T., Yoon J., Bringezu F., Warriner H., Zasadzinski J.A. More than a monolayer: relating lung surfactant structure and mechanics to composition. Biophys. J. 2004, 87(December (6)):4188-4202.
3. Blanco O., Pérez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: role of the different components in an efficient pulmonary surfactant?. Eur. J. Pharmacol. 2007, 568(July (1-3)):1-15.
4. Budai M., Reynaud-Angelin A., Szabó Z., Tóth S., Rontó G., Sage E., Gróf P. Effect of UVA radiation on membrane fluidity and radical decay in human fibroblasts as detected by spin labeled stearic acids. J. Photochem. Photobiol. B 2004, 77(December (1-3)):27-38.
5. Budai M., Szabó Z., Szogyi M., Gróf P. Molecular interactions between DPPC and morphine derivatives: a DSC and EPR study. Int. J. Pharm. 2003, 250(January (1)):239-250.
6. Bummer P., Sanders L., Pauly T., Gillespie M. In vitro inactivation of pulmonary surfactant replacement preparations by serum albumin. Am. J. Med. Sci. 1994, 307:401-404.
7. Casals C., Cañadas O. Role of lipid ordered/disordered phase coexistence in pulmonary surfactant function. Biochim. Biophys. Acta 2012, 1818(11):2550-2562.
8. Clements J.A., Avery M.E. Lung surfactant and neonatal respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1998, 157(4 Pt. 2):59-66.
9. Creuwels L.A., van Golde L.M., Haagsman H.P. The pulmonary surfactant system: biochemical and clinical aspects. Lung 1997, 175(1):1-39.
10. Daniels C.B., Orgeig S. Pulmonary surfactant: the key to the evolution of air breathing. News Physiol. Sci. 2003, 18(August):151-157. (review).
11. de la Serna B.J., Perez-Gil J., Simonsen A.C., Bagatolli L.A. Cholesterol rules: direct observation of the coexistence of two fluid phases in native pulmonary surfactant membranes at physiological temperatures. J. Biol. Chem. 2004, 279(September (39)):40715-40722.
12. de Sousa Neto D., Salmon C.E., Alonso A., Tabak M. Interaction of bovine serum albumin (BSA) with ionic surfactants evaluated by electron paramagnetic resonance (EPR) spectroscopy. Colloids Surf. B: Biointerfaces 2009, 70(1):147-156.
13. Dhar P., Eck E., Israelachvili J.N., Lee D.W., Min Y., Ramachandran A., Waring A.J., Zasadzinski J.A. Lipid-protein interactions alter line tensions and domain size distributions in lung surfactant monolayers. Biophys. J. 2012, 102(January (1)):56-65.
14. Diemel R.V., Snel M.M., Van Golde L.M., Putz G., Haagsman H.P., Batenburg J.J. Effects of cholesterol on surface activity and surface topography of spread surfactant films. Biophys. J. 2002, 93(August (4)):1391-1401.
15. Ding J., Takamoto D.Y., von Nahmen A., Lipp M.M., Lee K.Y., Waring A.J., Zasadzinski J.A. Effects of lung surfactant proteins, SP-B and SP-C, and palmitic acid on monolayer stability. Biophys. J. May 2001, 80(5):2262-2272.
16. Discher B.M., Maloney K.M., Grainger D.W., Sousa C.A., Hall S.B. Neutral lipids induce critical behavior in interfacial monolayers of pulmonary surfactant. Biochemistry 2002, 41(December (50)):15007-15016.
17. Enhorning G. Pulsating bubble technique for evaluating pulmonary surfactant. J. Appl. Physiol. 1977, 43:198-203.
18. Greene K., Wright J., Steinberg K., Ruzinski J., Caldwell E., Wong W., Hull W., Whitsett J., Akino T., Kuroki Y., Nagae H., Hudson L., Martin T. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am. J. Respir. Crit. Care Med. 1999, 160:1843-1850.
19. Gregory T., Longmore W., Moxley M., Whitsett J., Reed C., Fowler A., Hudson L., Maunder R., Crim C., Hyers T. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J. Clin. Invest. 1991, 88:1976-1981.
20. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur. Respir. J. 1999, 13(6):1455-1476.
21. Gross N., Kellam M., Young J., Krishnasamy S., Dhand R. Separation of alveolar surfactant into subtypes. A comparison of methods. Am. J. Respir. Crit. Care Med. 2000, 152:517-522.
22. Günther A., Ruppert C., Schmidt R., Markart P., Grimminger F., Walmrath D., Seeger W. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir. Res. 2001, 2(6):353-364.
23. Hager, A., De Paoli, T., 2001. Method for extracting and purifying pulmonary surfactant. United States Patent US 6172203 B1, January.
24. Hayes G., Jost P.C. Lipid spin labels in biological membranes. Spin Labeling: Theory and applications 1976, (chapter 12). L.J. Berliner (Ed.).
25. Hook G.E., Spalding J.W., Ortner M.J., Tombropoulos E.G., Chignell C.F. Investigation of phospholipids of the pulmonary extracellular lining by electron paramagnetic resonance. The effects of phosphatidylglycerol and unsaturated phosphatidylcholines on the fluidity of dipalmitoylphosphatidylcholine. Biochem. J. 1984, 223(2):533-542.
26. Hubbell W.L., McConnell H.M. Molecular motion in spin-labeled phospholipids and membranes. J. Am. Chem. Soc. 1971, 93(January (2)):314-326.
27. Keating E., Rahman L., Francis J., Petersen A., Possmayer F., Veldhuizen R., Petersen N.O. Effect of cholesterol on the biophysical and physiological properties of a clinical pulmonary surfactant. Biophys. J. 2007, 93(August (4)):1391-1401.
28. Keith A., Snipes W. Viscosity of cellular protoplasm. Science 1974, 183:666-668.
29. Korlach J., Schwille P., Webb W.W., Feigenson G.W. Characterization of lipid bilayer phases by confocal microscopy and fluorescence correlation spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(July (15)):8461-8466.
30. Lange Y., Steck T.L. Cholesterol-rich intracellular membranes: a precursor to the plasma membrane. J. Biol. Chem. 1985, 260(December (29)):15592-15597.
31. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin Phenol reagent. J. Biol. Chem. 1951, 193:265-275.
32. Lu K.W., William Taeusch H., Robertson B., Goerke J., Clements J.A. Polymer-surfactant treatment of meconium-induced acute lung injury. Am. J. Respir. Crit. Care Med. 2000, 162:623-628.
33. Maitra G., Inchley K., Novick R.J., Veldhuizen R.A., Lewis J.F., Possmayer F. Acute lung injury and lung transplantation influence in vitro subtype conversion of pulmonary surfactant. Am. J. Physiol. Lung Cell Mol. Physiol. 2002, 282(1):67-74.
34. Markart P., Ruppert C., Wygrecka M., Colaris T., Dahal B., Walmrath D., Harbach H., Wilhelm J., Seeger W., Schmidt R., Guenther A. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. Thorax 2007, 62(July (7)):588-594.
35. Marsh D., Horvath L.I. Structure, dynamic and composition of the lipid-protein interface: perspectives from spin labelling. BBA 1998, 1376:267-296.
36. Martínez Sarrasague M., Cimato A., Rubin de Celis E., Facorro G. Influence of serum protein and albumin addition on the structure and activity of an exogenous pulmonary surfactant. Respir Physiol Neurobiol 2011, 175(March (3)):316-321.
37. Martínez Sarrasague M., Cimato A., Rubin de Celis E., Facorro G. Effect of serum proteins on an exogenous pulmonary surfactant: ESR analysis of structural changes and their relation with surfactant activity. Respir Physiol Neurobiol 2012, 183(July (1)):48-57.
38. Matthay M., Zemans R. The acute respiratory distress syndrome: pathogenesis and treatment. Annu. Rev. Pathol. 2011, 6(February):147-163. (review).
39. Morse P., Lusczakoski D., Simpson D. Internal viscosity of red blood cells and hemoglobin-free released ghosts: a spin label study. Biochemistry 1979, 18:5021-5029.
40. Nag K., Pao J.S., Harbottle R.R., Possmayer F., Petersen N.O., Bagatolli L.A. Segregation of saturated chain lipids in pulmonary surfactant films and bilayers. Biophys. J. 2002, 82(April (4)):2041-2051.
41. Nag K., Hillier A., Parsons K., Garcia M.F. Interactions of serum with lung surfactant extract in the bronchiolar and alveolar airway models. Respir Physiol Neurobiol 2007, 157(2-3):411-424.
42. Nusair N.A., Mayo D.J., Dorozenski T.D., Cardon T.B., Inbaraj J.J., Karp E.S., Newstadt J.P., Grosser S.M., Lorigan G.A. Time-resolved EPR immersion depth studies of a transmembrane peptide incorporated into bicelles. Biochim. Biophys. Acta 2012, 1818:821-828.
43. Ochs M., Schüttler M., Stichtenoth G., Herting E. Morphological alterations of exogenoussurfactant inhibited by meconium can be prevented by dextran. Respir. Res. 2006, 7(June):86.
44. Otsubo E., Takei T. Characterization of the surface activity of a synthetic surfactant with albumin. Biol. Pharm. Bull. 2002, 25:1519-1523.
45. Poulain F.R., Clements J.A. Pulmonary surfactant therapy. West. J. Med. 1995, 162(1):43-50.
46. Scherfeld D., Kahya N., Schwille P. Lipid dynamics and domain formation in model membranes composed of ternary mixtures of unsaturated and saturated phosphatidylcholines and cholesterol. Biophys. J. 2003, 85(December (6)):3758-3768.
47. Schmidt R., Meier U., Yabut-Perez M., Walmrath D., Grimminger F., Seeger W., Günther A. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am. J. Respir. Crit. Care Med. 2001, 163(1):95-100.
48. Seeger W., Stöhr G., Wolf H., Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J. Appl. Physiol. 1985, 58:326-338.
49. Stewart J.C.M. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 1980, 104:10-14.
50. Ueda T., Ikegami M., Jobe A. Surfactant subtypes. In vitro conversion, in vivo function, and effects of serum proteins. Am. J. Respir. Crit. Care Med. 1994, 149(5):1254-1259.
51. Veldhuizen R.A., Inchley K., Hearn S.A., Lewis J.F., Possmayer F. Degradation of surfactant-associated protein B (SP-B) during in vitro conversion of large to small surfactant aggregates. Biochem. J. 1993, 1(295):141-147.
52. Veldhuizen R.A., Marcou J., Yao L.J., Ito Y., Lewis J.F. Alveolar surfactant aggregate conversion in ventilated normal and injured rabbits. Am. J. Physiol. 1996, 270:152-158.
53. Warriner H., Ding J., Waring A., Zasadzinski J. A concentration-dependent mechanism by which serum albumin inactivates replacement lung surfactants. Biophys. J. 2002, 82:835-842.
54. William Taeusch H., Lu K.W., Goerke J., Clements J.A. Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am. J. Respir. Crit. Care Med. 1999, 159:1391-1395.
55. Willson D.F., Notter R.H. The future of exogenous surfactant therapy. Respir. Care 2011, 56(9):1369-1386. (discussion 1386-1388). 10.4187/respcare.01306.